Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis

The study found a lower risk of gastrointestinal side effects for Prexige compared to ibuprofen and naproxen, but the incidence of serious liver abnormalities was higher for the COX-2 than for the NSAIDs.

More from Archive

More from Pink Sheet